The affected products are Amikacin Sulfate Injection Lot VEAC025 and Prochlorperazine Edisylate Injection Lot VPCA172. Both products were distributed to wholesalers in the U.S. in 2018.
The microbial growth may indicate a lack of sterility in other lots, according to Heritage.
“Nonsterile injectable products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, organ damage or death,” the company said in its recall notice.
Both drugs are manufactured by Emcure Pharmaceuticals and distributed by Heritage.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
